MedTrace Logo

Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

NCT02921984 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-03-20

No results posted yet for this study

Summary

The role of postoperative concurrent chemotherapy (CCT) has not been established for salivary gland tumors (SGTs). This prospective study was conducted to evaluate the feasibility and safety of customized CCT regimens based on the gene targets of SGTs.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel only: 80 mg/m2 on day one, every 21 days if

RADIATION

Intensity-modulated radiotherapy

a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks

DRUG

Pemetrexed

Pemetrexed only: 500 mg/m2 on day one, every 21 days

DRUG

Cisplatin

Cisplatin only: 70 mg/m2 on day one to day three, every 21 days

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    lead OTHER

Principal Investigators

  • Guopei Zhu · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-12-31
Completion
2017-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02921984 on ClinicalTrials.gov